How to Protect Yourself from COVID-19 – Free eBook

The Beljanski Foundation is sponsoring a new clinical trial for patients with Long COVID because of the urgent need for a new and successful treatment. Anecdotal reports from patients experiencing lingering symptoms from an infection with SARS-CoV-2 started to emerge shortly after the beginning of the pandemic, and the term “Long COVID” was coined to name this condition and alert the scientific community. Upwards of 65 million people worldwide are now suffering from this condition. The goal is to test whether the administration of a special preparation of small RNA fragments, originally developed by Dr. Mirko Beljanski, will work by stimulating stem cells in the bone marrow to produce new immune cells. Previous research conducted on this special preparation at Cancer Treatment Centers of America confirmed its safety and effectiveness for treating thrombocytopenia (low platelets) caused by chemotherapy. Thrombocytopenia has been seen in a significant number of Long COVID patients, and low platelets are associated with fatigue – a major symptom of Long COVID. The trial will also reveal the potential of the RNA fragments to re-balance immunity in these patients.

While the critical role of RNA primers was first discovered by Okazaki, those short segments of RNA acting as primers for initiating the synthesis of new strands of DNA were originally developed by Dr. Beljanski, a French Biologist from the Pasteur Institute in Paris, France. The fragments work by stimulating stem cells in the bone marrow to produce our immune cells. They have been available as dietary ingredients in the US since the 90s, and it is a commercial preparation made available by Maison Beljanski, which will be used for the clinical trial. Enrollment for the clinical trial is already on its way in Europe. The findings are expected to provide valuable insight into whether improving bone marrow function and patient immunity is a pathway for successful Long COVID treatment.

“Platelet levels have been measured in depressed patients and have been found to be decreased when compared to normal controls. Therefore, interference in this process might be a promising avenue for further research to address mild thrombocytopenia in people with Long COVID, along with the most common side effects of this condition, which are fatigue and depression,” says Dr. John Hall, Director of Research at the Beljanski Foundation.